問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Thoracic Medicine

Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

Division of Thoracic Surgery

Division of General Internal Medicine

更新時間：2023-09-19

郭漢彬Kuo, Han-Pin
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • q8828@tmu.edu.tw

Recruiting Trial

22Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭漢彬

Taipei Medical University Hospital

Division of Thoracic Medicine

List

16Cases

2020-01-03 - 2021-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Condition/Disease

    AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Test Drug

    AR-301 Tosatoxumab

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites

2022-05-01 - 2026-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-09-01 - 2022-03-31

Phase III

PONENTE: A multicenter, open-label, Phase 3b trial for adult patients with severe eosinophilic leukocyte asthma who are treated with high-dose corticosteroid inhalers, plus long-acting beta 2 agonists and oral corticosteroids for long-term treatment, to evaluate subcutaneously Efficacy and safety of 30 mg injection of Benralizumab for reducing oral corticosteroid dosage

  • Condition/Disease

    Severe eosinophilic leukocyte asthma

  • Test Drug

    Benralizumab

Participate Sites
8Sites

Recruiting8Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬
Taipei Medical University Hospital

Division of Thoracic Medicine

2021-08-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2021-07-27 - 2025-06-30

Phase II

A Phase II Study to Evaluate the Efficacy and Safety of FB825 in Adult Patients with Moderate-to-severe Allergic Asthma

  • Condition/Disease

    Allergic Asthma

  • Test Drug

    FB825

Participate Sites
17Sites

Not yet recruiting5Sites

Recruiting12Sites

2021-06-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB